Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

Wealthfront Advisers LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 84.4% during the fourth quarter, according to the company in its most recent disclosure with the ...

The most recent trading session ended with Moderna (MRNA) standing at $34.71, reflecting a +0.26% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.64%.

National Institutes of Health officials have urged scientists to remove all references to mRNA vaccine technology from their ...

A senior official at the NIH's National Cancer Institute confirmed to KFF that NIH acting Director Matthew Memoli "sent an ...

The Florida surgeon general in January 2024 called for a halt in the use of COVID mRNA vaccines. And in Texas, Attorney ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday ...

In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.

The work on mRNA vaccines is especially important for bird flu. Most flu vaccines are currently made using a decades-old ...

NPR reports on the National Institutes of Health funding cuts with insight from two NIH staffers and one person familiar with NIH's activities who requested anonymity because they were not authorized ...